Buy-rated reports

573 tickers rated Buy
Ranks this page's recent reports by score.
Sprouts Farmers Market, Inc.
SFM·Consumer Staples
A ★★★★Buy
Current$49.70
Target$57.00
Return+14.7%
Oct 31, 2026

Sprouts offers a differentiated, cash-generative specialty-grocery franchise at a compressed valuation with meaningful store-expansion potential, but weak comparable-store sales and rising reinvestment requirements threaten earnings recovery.

Score
77
Prosperity Bancshares, Inc.
PB·Financials
A ★★★★Buy
Current$71.98
Target$82.39
Return+14.5%
Oct 31, 2026

Prosperity Bancshares offers attractive valuation, dividend growth, and acquisition-driven earnings upside supported by a valuable Texas deposit franchise, although merger integration and commercial credit risks could delay shareholder returns.

Score
80
Kirby Corporation
KEX·Industrials
A ★★★★Buy
Current$143.93
Target$168.00
Return+16.7%
Oct 31, 2026

Kirby combines a scale-advantaged domestic tank-barge franchise with expanding power-generation demand and strong cash returns, although cyclical freight markets, fuel inflation, and capital intensity constrain its long-term upside.

Score
81
Zurn Elkay Water Solutions Corporation
ZWS·Industrials
A ★★★★Buy
Current$44.80
Target$48.72
Return+8.8%
Oct 31, 2026

Zurn Elkay combines durable water-infrastructure demand, strong cash conversion and attractive capital returns with a favorable historical valuation, although cyclical construction demand and acquisition execution constrain near-term upside.

Score
82
Insulet Corporation
PODD·Healthcare
A ★★★★Buy
Current$149.68
Target$169.84
Return+13.5%
Oct 31, 2026

Insulet's recurring Omnipod revenue and global automated insulin delivery expansion support durable earnings growth at a compressed valuation, although product recalls and manufacturing reliability remain material threats.

Score
76
Encompass Health Corporation
EHC·Healthcare
A ★★★★Buy
Current$135.90
Target$149.10
Return+9.7%
Oct 31, 2026

Encompass Health can compound earnings through growing rehabilitation demand, hospital expansion, and operating leverage, although reimbursement constraints, labor inflation, and heavy capital spending limit its valuation margin of safety.

Score
81
Reinsurance Group of America, Incorporated
RGA·Financials
A ★★★★Buy
Current$264.73
Target$300.00
Return+13.3%
Oct 31, 2026

RGA offers durable life-reinsurance earnings growth and attractive returns on capital at a reasonable forward earnings multiple, although elevated historical book-value valuation and potential mortality or credit shocks constrain the margin of safety.

Score
78
United Therapeutics Corporation
UTHR·Healthcare
A ★★★★Buy
Current$598.72
Target$650.00
Return+8.6%
Oct 31, 2026

United Therapeutics combines exceptional specialty-pharma profitability with transformative pulmonary-treatment catalysts, although elevated historical valuation and regulatory uncertainty limit the margin of safety.

Score
75
Leonardo DRS, Inc.
DRS·Industrials
A ★★★★Buy
Current$37.68
Target$42.00
Return+11.5%
Oct 31, 2026

Leonardo DRS combines durable defense technology demand, rising backlog, and improving capital returns with long-term earnings growth potential, although government procurement concentration and demanding valuation limit its margin of safety.

Score
82
Regency Centers Corporation
REG·Real Estate
A ★★★★Buy
Current$74.59
Target$81.12
Return+8.8%
Oct 31, 2026

Regency Centers combines resilient grocery-anchored rental income, strong occupancy, and development-led FFO growth, but higher financing costs and tenant weakness could constrain returns.

Score
75
DoorDash, Inc.
DASH·Consumer Discretionary
A ★★★★Buy
Current$178.99
Target$201.35
Return+12.5%
Oct 31, 2026

DoorDash combines a scaled global local-commerce network with rapidly improving profitability and cash generation, but its proposed Instacart acquisition could introduce significant financing, dilution, and integration risks.

Score
76
Banco Bradesco S.A.
BBD·Financials
A ★★★★Buy
Current$2.55
Target$3.30
Return+29.4%
Oct 31, 2026

Banco Bradesco offers discounted exposure to a recovering Brazilian banking and insurance franchise, although rising credit delinquency and post-capital-increase dilution threaten the durability of per-share earnings growth.

Score
77